Last reviewed · How we verify

Placebo to budesonide inhaler

Organon and Co · FDA-approved active Small molecule

Placebo to budesonide inhaler is a Inhaled corticosteroid Small molecule drug developed by Organon and Co. It is currently FDA-approved for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).

Budesonide is a corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors and suppressing inflammatory cytokine production.

Budesonide is a corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors and suppressing inflammatory cytokine production. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).

At a glance

Generic namePlacebo to budesonide inhaler
SponsorOrganon and Co
Drug classInhaled corticosteroid
TargetGlucocorticoid receptor
ModalitySmall molecule
Therapeutic areaRespiratory/Pulmonology
PhaseFDA-approved

Mechanism of action

Budesonide acts as a topical corticosteroid in the lungs, binding to intracellular glucocorticoid receptors and modulating gene transcription to decrease production of inflammatory mediators such as cytokines and adhesion molecules. This reduces airway edema, mucus production, and eosinophil infiltration, thereby improving airflow and reducing asthma symptoms. The inhaled route delivers the drug directly to the site of inflammation while minimizing systemic exposure.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo to budesonide inhaler

What is Placebo to budesonide inhaler?

Placebo to budesonide inhaler is a Inhaled corticosteroid drug developed by Organon and Co, indicated for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).

How does Placebo to budesonide inhaler work?

Budesonide is a corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors and suppressing inflammatory cytokine production.

What is Placebo to budesonide inhaler used for?

Placebo to budesonide inhaler is indicated for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).

Who makes Placebo to budesonide inhaler?

Placebo to budesonide inhaler is developed and marketed by Organon and Co (see full Organon and Co pipeline at /company/organon-and-co).

What drug class is Placebo to budesonide inhaler in?

Placebo to budesonide inhaler belongs to the Inhaled corticosteroid class. See all Inhaled corticosteroid drugs at /class/inhaled-corticosteroid.

What development phase is Placebo to budesonide inhaler in?

Placebo to budesonide inhaler is FDA-approved (marketed).

What are the side effects of Placebo to budesonide inhaler?

Common side effects of Placebo to budesonide inhaler include Oral candidiasis, Dysphonia/hoarseness, Tremor, Headache, Throat irritation.

What does Placebo to budesonide inhaler target?

Placebo to budesonide inhaler targets Glucocorticoid receptor and is a Inhaled corticosteroid.

Related